- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Chronic Pulmonary Aspergillosis.
Displaying page 1 of 1.
EudraCT Number: 2016-003921-40 | Sponsor Protocol Number: 2016IF002 | Start Date*: 2017-07-21 | |||||||||||||||||||||||||||||||
Sponsor Name:University Hospital of South Manchester NHS Foundation Trust | |||||||||||||||||||||||||||||||||
Full Title: Open label study of the efficacy and safety of isavuconazole for the treatment of Chronic Pulmonary Aspergillosis | |||||||||||||||||||||||||||||||||
Medical condition: Chronic Pulmonary Aspergillosis | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-000972-14 | Sponsor Protocol Number: CPAAARI | Start Date*: 2018-07-04 | |||||||||||
Sponsor Name:CHU DE POITIERS | |||||||||||||
Full Title: Therapeutic efficacy comparison of a six-month treatment by itraconazole and nebulised Ambisome® versus treatment by itraconazole alone in non- or mildly- immunocompromised patients with Chronic Pu... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006648-23 | Sponsor Protocol Number: CIGE025A2437 | Start Date*: 2008-11-12 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis | ||||||||||||||||||
Medical condition: Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) NL (Prematurely Ended) GB (Prematurely Ended) IE (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-003435-11 | Sponsor Protocol Number: VL2397-201 | Start Date*: 2018-08-14 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Vical Incorporated | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Immunocompromised Adults | ||||||||||||||||||||||||||||||||||||||
Medical condition: Invasive Aspergillosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004910-27 | Sponsor Protocol Number: MK-0991-074 | Start Date*: 2015-02-24 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Asp... | ||
Medical condition: Candida or Aspergillus Infections | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2018-002565-18 | Sponsor Protocol Number: SCY-078-206 | Start Date*: 2019-10-04 | |||||||||||
Sponsor Name:SCYNEXIS, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Coadministration of SCY-078 with Voriconazole in Patients with Invasive Pulmonary Aspergillosis (SCYNERGIA) | |||||||||||||
Medical condition: Patients with Invasive Pulmonary Aspergillosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Ongoing) ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000381-29 | Sponsor Protocol Number: SCY-078-301 | Start Date*: 2017-07-17 |
Sponsor Name:SCYNEXIS, Inc. | ||
Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI) | ||
Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000244-26 | Sponsor Protocol Number: PC-ASP-004 | Start Date*: 2018-08-21 | ||||||||||||||||
Sponsor Name:Pulmocide Ltd | ||||||||||||||||||
Full Title: A double-blind, placebo-controlled study to assess the effects of inhaled PC945 in the treatment of culture-positive Aspergillus or Candida fungal bronchitis in subjects with moderate to severe ast... | ||||||||||||||||||
Medical condition: Pulmonary aspergillosis and candidiasis of lung | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-000679-16 | Sponsor Protocol Number: EORTC 06023 | Start Date*: 2005-05-17 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Randomized phase II trial with infliximab (Remicade) in patients with myelodysplastic syndrome and a relatively low risk of developing acute leukemia | |||||||||||||
Medical condition: myelodysplastic syndrome (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004784-58 | Sponsor Protocol Number: MRI-0143 | Start Date*: 2007-06-22 | |||||||||||
Sponsor Name:University of Leuven | |||||||||||||
Full Title: Effect of infliximab on inflammatory and fibrous lesions in patients with intestinal Crohn’s disease | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.